PIA
CYTK icon

Piedmont Investment Advisors’s Cytokinetics CYTK Stock Holding History

Piedmont Investment Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-13,594
Closed -$110K – 1014
2019
Q1 		$110K Buy
13,594
+727
+6% +$5.34K ﹤0.01% 1124
2018
Q4 		$81K Buy
12,867
+425
+3% +$3.12K ﹤0.01% 1016
2018
Q3 		$123K Buy
12,442
+657
+6% +$5.27K 0.01% 1018
2018
Q2 		$98K Buy
11,785
+959
+9% +$7.98K ﹤0.01% 1105
2018
Q1 		$78K Buy
10,826
+415
+4% +$3.56K ﹤0.01% 758
2017
Q4 		$85K Sell
10,411
-578
-5% -$6.56K ﹤0.01% 754
2017
Q3 		$159K Buy
+10,989
New +$150K ﹤0.01% 745

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Piedmont Investment Advisors's CYTK Position: Q2 2019 in Review

Piedmont Investment Advisors sold out of Cytokinetics (CYTK) in Q2 2019, closing a stake of 13,594 shares — an estimated $110K sold.

Piedmont Investment Advisors first reported a position in CYTK in Q3 2017 and held it in 7 quarters. The position peaked at $159K in Q3 2017. 134 funds tracked by Wall St. Rank hold CYTK as of Q2 2019.

  • Piedmont Investment Advisors reported no remaining Cytokinetics position as of Q2 2019 after selling out during the quarter.
  • Piedmont Investment Advisors sold 13,594 Cytokinetics shares in Q2 2019, an estimated $110K.
  • Piedmont Investment Advisors first reported a position in Cytokinetics in Q3 2017 and held it in 7 quarters.
  • Piedmont Investment Advisors's Cytokinetics position peaked at $159K in Q3 2017.
  • 134 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2019.

Based on Piedmont Investment Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.